Advances in medical treatment have improved the prognosis for patients with cancer. While
significant progression has been made in eradicating certain malignant diseases, a growing …

Amphotericin B remains the treatment of choice for systemic fungal infections, but
amphotericin B is toxic and is often not effective in treating disseminated infections …

The case of a female patient with acute lymphoblastic leukaemia and chronic disseminated
candidiasis, who was refractory to 1.8 g conventional amphotericin B therapy, is reported …

Twelve patients with hematologic malignancies complicated by fungal infections were
treated with liposomal amphotericin B (L-AmpB). Nine patients were granulocytopenic; the …

Summary Abstract Liposomal amphotericin B (AmBisome®) is a lipid-associated formulation
of the broad-spectrum polyene antifungal agent amphotericin B. It is active against clinically …

The relative efficacies of free amphotericin B (Amp B) and liposome-encapsulated Amp B (L-
AmpB) in the treatment of established Candida albicans infection in mice rendered …

Fungal infections continue to be a major problem in the management of
immunocompromised patients. Despite its formidable toxicity and treatment failures …

The use of high-dose chemotherapy and the subsequent prolonged neutropenia in patients
with haematological diseases has resulted in an increased incidence of fungal infections …

Liposomal amphotericin B (AmBisome) was used for suspected or confirmed fungal infection
complicating 133 neutropenic episodes in 116 patients not tolerating, or not responding to …

Amphotericin B is commonly used in the intensive care unit to treat invasive fungal infection.
This medication is associated with a number of adverse events during infusion, such as …